Figure 1.

Survival among patients randomized to nivolumab or IC as first‐line treatment for R/M SCCHN after progressing on or after platinum therapy (within 6 months) in the adjuvant or primary (i.e., with radiation) setting for locally advanced disease: Kaplan‐Meier plot of OS (A) and treatment effect on OS (B) among patients randomized to nivolumab or IC as first‐line treatment for R/M SCCHN after progressing on or after platinum therapy.

Abbreviations: CI, confidence interval; HPV, human papillomavirus; HR, hazard ratio; IC, investigator's choice; mo, months; NE, not estimable; Nivo, nivolumab; OS, overall survival; R/M, recurrent or metastatic; SCCHN, squamous cell carcinoma of the head and neck.